The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes after second-line treatment in non-small cell lung cancer (NSCLC) patients treated with immunotherapy.
 
Melina Elpi Marmarelis
Stock and Other Ownership Interests - Bluebird Bio; Gilead Sciences; Johnson & Johnson; Merck; Pfizer; Portola Pharmaceuticals
Honoraria - Health Advances (I); Novocure; Targeted Oncology
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Lilly (Inst); Trizell (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Novocure
Other Relationship - Novartis
 
Wei-Ting Hwang
Research Funding - Janssen (I)
 
Yu-Xiao Yang
No Relationships to Disclose
 
Christine Agnes Ciunci
Honoraria - Imedex; Imedex
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); MacroGenics (Inst); Merck (Inst)
 
Aditi Puri Singh
No Relationships to Disclose
 
Charu Aggarwal
Consulting or Advisory Role - AstraZeneca; Celgene; Genentech; Lilly; Merck
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I)
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst)
 
Roger B. Cohen
Consulting or Advisory Role - Alkermes; AstraZeneca; Cantargia AB; Genocea Biosciences; Heat Biologics; Innate Pharma; Kyn therapeutics; Takeda
Research Funding - Celldex (Inst); Genocea Biosciences (Inst); Heat Biologics (Inst); Innate Pharma (Inst); Kyn therapeutics (Inst); Merck (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Alkermes; Genocea Biosciences; Heat Biologics; Innate Pharma; Kyn therapeutics; Takeda
 
Corey J. Langer
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck; Novocure; Pfizer; Takeda
Research Funding - Advantagene (Inst); Ariad (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Lilly; Merck (Inst); Stem CentRx (Inst)
Other Relationship - Amgen; Lilly; Peregrine Pharmaceuticals; Synta
 
Ronac Mamtani
Honoraria - Flatiron Health
Consulting or Advisory Role - Genentech/Roche; Seattle Genetics/Astellas
 
Joshua Bauml
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; Guardant Health; Janssen; Merck; Novartis; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Carevive Systems (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Takeda (Inst)